Chen, D.; Untaru, R.; Stavropoulou, G.; Assadi-Khansari, B.; Kelly, C.; Croft, A.J.; Sugito, S.; Collins, N.J.; Sverdlov, A.L.; Ngo, D.T.M.
Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE). J. Clin. Med. 2023, 12, 2790.
https://doi.org/10.3390/jcm12082790
AMA Style
Chen D, Untaru R, Stavropoulou G, Assadi-Khansari B, Kelly C, Croft AJ, Sugito S, Collins NJ, Sverdlov AL, Ngo DTM.
Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE). Journal of Clinical Medicine. 2023; 12(8):2790.
https://doi.org/10.3390/jcm12082790
Chicago/Turabian Style
Chen, Dongqing, Rossana Untaru, Glykeria Stavropoulou, Bahador Assadi-Khansari, Conagh Kelly, Amanda J. Croft, Stuart Sugito, Nicholas J. Collins, Aaron L. Sverdlov, and Doan T. M. Ngo.
2023. "Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)" Journal of Clinical Medicine 12, no. 8: 2790.
https://doi.org/10.3390/jcm12082790
APA Style
Chen, D., Untaru, R., Stavropoulou, G., Assadi-Khansari, B., Kelly, C., Croft, A. J., Sugito, S., Collins, N. J., Sverdlov, A. L., & Ngo, D. T. M.
(2023). Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE). Journal of Clinical Medicine, 12(8), 2790.
https://doi.org/10.3390/jcm12082790